Precision Glyco‐Modulated GcMAF2.0 Targets CLEC10A to Bidirectionally Re‐Wire Macrophage States: Cross‐Species Evidence, Mechanistic Omics and Translational Horizons

Macrophages orchestrate inflammation, tissue repair and tumour surveillance, yet macrophage‐targeted strategies such as CSF1R inhibition, CD47 blockade or TLR7/8 agonists have so far yielded only modest, context‐restricted benefit. The C‐type lectin CLEC10A (MGL/CD301) recognises a single terminal α‐N‐acetylgalactosamine (α‐GalNAc) and couples this minimalist glycan cue to context‐dependent inflammatory or reparative programmes, making it an attractive target for precision macrophage re‐programming. This review synthesises mechanistic, pre‐clinical and clinical data on Gc protein‐derived macrophage‐activating factor 2.0 (GcMAF2.0), a mono‐α‐GalNAc derivative of vitamin‐D‐binding protein that engages CLEC10A with high avidity. We summarise lessons from heterogeneous “GcMAF1.0” products, outline GMP workflows that yield EF‐M1/EF‐M2, and review CLEC10A‐centred signalling and metabolic re‐wiring, including SYK versus STAT6/PPARγ cascades and shifts in arginine, glucose and fatty‐acid metabolism. Cross‐species data from rodent inflammation models, human and canine myeloid cells, barrier‐tissue and tumour models, and mesoscopic platforms indicate that α‐GalNAc ligands and EF‐M2 bias macrophage profiles and attenuate joint and barrier‐tissue inflammation. A randomised double‐blind placebo‐controlled trial of EF‐M2 in canine osteoarthritis links macrophage repolarisation to pain relief, gait restoration and serum ARG1/iNOS and IL‐10/TNF‐α shifts, providing disease‐modifying proof of concept. We also review the small, uncontrolled human experience with analytically characterised GcMAF2.0 (≈120 patient‐courses), noting favourable short‐term tolerability but low certainty of benefit and a need for randomised, lot‐traceable trials with mechanistic endpoints. Overall, we position the α‐GalNAc–CLEC10A axis as a tunable handle on macrophage plasticity and outline the experimental and regulatory priorities needed to translate GcMAF2.0 into evidence‐based immunotherapy.